Skip to main content
CMG Pharmaceutical Co., Ltd. logo

CMG Pharmaceutical Co., Ltd. - Investor Relations & Filings

Listed IPO Aug 2001
Ticker · 058820 ISIN · KR7058820002 KO Manufacturing
Open in API
Filings indexed 170 across all filing types
Latest filing 2025-03-12 Proxy Solicitation & In…
Country KR South Korea
Listing KO 058820 · 1 venue

About CMG Pharmaceutical Co., Ltd.

http://www.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the development of advanced drug delivery systems. The company's core competency is its Oral Thin Film (OTF), or Orally Dissolving Film (ODF), technology platform. This technology is used to develop improved new drugs, new formulations, and combination therapies designed to enhance patient convenience and efficacy. The company's portfolio includes prescription medications and general pharmaceuticals. As an affiliate of CHA Health Systems, CMG Pharmaceutical is actively engaged in research and development, managing a pipeline of drug candidates and conducting clinical trials.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for CMG Pharmaceutical. It contains the agenda for the 24th Annual General Meeting, including voting items such as financial statement approval, director/auditor remuneration limits, and details on electronic voting and proxy procedures. This document is a standard proxy statement/notice of meeting sent to shareholders to solicit votes and provide information for the upcoming AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by CMG Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the rationale for choosing this date despite regulatory requests for dispersion. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2025-03-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the shareholding status of Focus Asset Management in CMG Pharmaceutical, specifically noting a change in holdings due to an adjustment in the conversion price of convertible bonds. This type of filing is a standard regulatory disclosure for significant ownership thresholds, which falls under the 'Major Shareholding Notification' category.
2025-02-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from CMG Pharmaceutical regarding a significant change in financial results (revenue or profit/loss structure exceeding 15-30%). It provides a summary table of financial performance (revenue, operating profit, net income) and explains the reasons for the variance. This is a standard 'Earnings Release' (ER) format used in the Korean market to disclose preliminary financial results before the final audited annual report is published. FY 2024
2025-02-12 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price of convertible bonds (CB) due to a decline in the market price of the underlying stock. This type of filing, which details changes to capital structure instruments like convertible debt, falls under the 'Capital/Financing Update' category as it directly relates to the company's financing activities and capital structure adjustments.
2025-02-11 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from CMG Pharmaceutical regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments (convertible debt), falls under the category of Capital/Financing Update.
2024-12-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.